Teneobio and Poseida Announce License Agreement for the Use of UniDab® in CAR T-Cell Therapy

MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) — Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.